ATAI Life Sciences N.V. (ATAI) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2025. ATAI Life Sciences N.V. is a clinical-stage biopharmaceutical company focused on developing rapid-acting, durable mental health treatments, primarily utilizing psychedelic and non-psychedelic compounds. The company operates as a single reportable segment. Key strategic developments during the period include the pending acquisition of Beckley Psytech Limited, the acquisition of IntelGenx Corp. (rebranded as Nualtis Corp.), and a corporate redomiciliation plan to Delaware.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $0.7 million | $0.3 million | $2.3 million | $0.3 million |
| Net Loss (Attributable to Stockholders) | $(27.7) million | $(57.3) million | $(54.2) million | $(84.0) million |
| Net Loss Per Share (Basic & Diluted) | $(0.14) | $(0.36) | $(0.29) | $(0.53) |
| Cash and Cash Equivalents | $61.9 million (as of June 30, 2025) | |||
| Short-term Securities | $34.0 million (as of June 30, 2025) | |||
| Accumulated Deficit | $(754.4) million (as of June 30, 2025) | |||
| Operating Cash Flow (6 Months) | $(31.9) million | $(38.8) million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased significantly year-over-year, driven by $2.1 million in research and development services revenue from the Nualtis subsidiary (formerly IntelGenx). License revenue from the Otsuka agreement ceased in Q2 2025 following termination.
- Reduced Net Loss: Net loss attributable to stockholders decreased by approximately 52% in Q2 2025 compared to Q2 2024. This improvement was largely due to a reduction in non-cash fair value losses on assets and liabilities (specifically COMPASS Pathways and IntelGenx investments) and lower personnel expenses following workforce reductions.
- Debt Extinguishment: In May 2025, the company fully repaid its $21.8 million Hercules Term Loan Facility, incurring a $1.3 million loss on extinguishment of debt. As of June 30, 2025, the company had no outstanding long-term debt obligations.
- Capital Raises: The company raised approximately $59.1 million in a February 2025 public offering and $29.9 million in a June 2025 PIPE financing. A subsequent July 2025 PIPE financing raised an additional ~$50 million (subsequent event).
- Investment Portfolio: The company recognized a $3.8 million gain on other investments related to the Beckley Psytech escrow draw. Conversely, it recorded a $5.4 million loss on the fair value of its COMPASS Pathways holdings for the six months ended June 30, 2025.
Guidance, Outlook, and Risks
- Liquidity: Management expects existing cash, cash equivalents, and short-term securities ($95.9 million total) to fund operations for at least the next 12 months, potentially extending into the second half of 2027 based on current plans.
- Strategic Combination: The pending acquisition of Beckley Psytech is expected to close in Q4 2025, subject to shareholder approval. This transaction involves issuing approximately 105 million new shares.
- Redomiciliation: The company plans to redomicile from the Netherlands to Delaware to improve operational flexibility. This requires shareholder approval and involves a cross-border merger with a Luxembourg entity.
- Key Risks:
- Profitability: The company expects to incur significant losses for the foreseeable future and may never be profitable.
- Development Uncertainty: All product candidates are in clinical or preclinical stages; regulatory approval is not guaranteed.
- Transaction Risks: Failure to close the Beckley Psytech deal or the Redomiciliation could negatively impact the share price and operations.
- Market Volatility: Significant fluctuations in the fair value of investments (COMPASS, Bitcoin) and derivative liabilities impact reported net loss.
Investor Verification Checklist
- Beckley Psytech Closing Conditions: Verify the status of shareholder approvals and other closing conditions for the Beckley Psytech acquisition, which is critical for the company's pipeline expansion.
- Redomiciliation Approval: Confirm the timeline and shareholder vote results for the proposed move to Delaware.
- Cash Burn Rate: Monitor the rate of cash consumption against the $95.9 million liquidity position to validate the "into 2027" runway estimate.
- Investment Valuations: Review the fair value assumptions for the COMPASS Pathways investment and Bitcoin holdings, as these drive significant non-cash volatility in earnings.
- Nualtis Revenue Sustainability: Assess the durability of the new revenue stream from Nualtis (formerly IntelGenx) and the status of the Rizafilm supply agreement.